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Abstract: Herein, novel hybrid compounds of celecoxib and 2-aminoanthraquinone derivatives 
have been synthesized using condensation reactions of celecoxib with 2-aminoanthraquinone 
derivatives or 2-aminoanthraquinon with celecoxib derivatives. Celecoxib was reacted with 
different acid chlorides, 2-chloroethylisocyanate and bis (2-chloroethyl) amine hydrochloride. 
These intermediates were then reacted with 2-aminoanthraquinone. Also the same different 
acid chlorides and 2-chloroethylisocyanate were reacted with 2-aminoanthraquinone and 
the resulting intermediates were reacted with celecoxib to give isomers for the previous 
compounds. The antitumor activities against hepatic carcinoma tumor cell line (HEPG2) 
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have been investigated in vitro, and all these compounds showed promising activities, 
especially compound 3c, 7, and 12. Flexible docking studies involving AutoDock 4.2 
was investigated to identify the potential binding affinities and the mode of interaction 
of the hybrid compounds into two protein tyrosine kinases namely, SRC (Pp60v-src) and 
platelet-derived growth factor receptor, PDGFR (c-Kit). The compounds in this study have 
a preferential affinity for the c-Kit PDGFR PTK over the non-receptor tyrosine kinase  
SRC (Pp60v-src). 
Keywords: antitumor; anthraquinone; celecoxib; HEPG2; docking; protein kinase activities 
 
1. Introduction 
Cancer is one of the most widespread serious diseases. It is characterized by uncontrolled  
growth of abnormal cells. The growth and metastasis of cancer cells are dependent on angiogenesis; 
Therefore, affecting angiogenesis will be of great importance in inhibition of tumor growth, invasion, 
and metastasis [1]. Prostaglandins are inflammatory mediators which are highly expressed in cancer 
angiogenesis. Prostaglandins are derived from arachidonic acid by either Cox-1 or Cox-2 [2–4]. Cox-2 
modulates cell proliferation and the apoptosis process, which plays an important role in cancer 
progression both in human and animal models malignancies [5]. It was shown that Cox-2 is over 
expressed in various cancers and this over expression protects cancer cells against several apoptotic 
stimuli [6]. A further study showed that knock-out of the Cox-2 gene could inhibit tumorgenesis [7]. 
Several new clinical studies were performed on celecoxib, a selective Cox-2 inhibitor which proved its 
effectiveness in many types of cancer including colorectal cancer, prostate cancer, breast cancer,  
non-small cell lung cancer [8,9], ovarian cancer [10], head and neck squamous cell carcinoma [11]. 
Another potential mechanism for anticancer agents is by targeting the DNA by intercalating agents such 
as anthraquinones [12]. These compounds have long been used as effective anticancer drugs against  
a broad spectrum of tumors. Depending on their chemical structures, anthraquinone drugs can kill tumor 
cells by diverse mechanisms including apoptosis. Apoptosis has been suggested to play an important 
role in the therapeutic activity of anthraquinone drugs on tumor cells. The apoptotic process triggered 
by mitoxantrone, an anthraquinone derivative, was mediated by caspase-3 activation [13]. Moreover, 
anthraquinone derivatives can inhibit tumor associated angiogenesis through inhibition of extracellular 
signal-regulated kinase [14]. Protein-tyrosine kinases (PTKs) are the key intermediates in cell signaling 
pathways that regulate cell growth and apoptosis. Altered functions of individual protein kinases result 
in numerous pathological conditions, including uncontrolled cell proliferation [15]. Tyrosine kinase 
inhibitors can be considered as a target for anti-angiogenesis and applied as a new model of cancer 
therapy [16]. With the emergence of in vitro biochemical assays and the development of biochemical 
and genetic studies, the drug discovery paradigm has shifted from the animal model screening approach 
to the target-focused ligand discovery model. This concept has led to many drugs reaching the  
market [17]. Computer prediction of the interaction between enzymes and small molecules has now 
advanced to the point that it allows accurate prediction of bound conformations and binding constants. 
Docking of the molecules into their respective 3D macromolecular targets is a widely used method for 
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lead optimization. One of the most well-known docking programs is AutoDock [18]. In recent years 
focusing on new anticancer drugs has become a major challenge. The combination of two different 
mechanisms in one compound is one of the major tools to find out more potentially active anticancer 
drugs. Thus, in the current study, we combine the two moieties celecoxib and anthraquinones in one 
hybrid structure aiming to increase their angiogenic effect to produce new potent anticancer agents. 
2. Results and Discussion 
2.1. Chemistry 
Compounds 2a was obtained according to the reported method [19] while compounds 2b, c  
were obtained by fusion of celecoxib 1 and 2-chloropropanoyl chloride, or chlorobutyryl chloride. 
Compounds 2a–c were subjected to condensation with 2-aminoanthraquinone 8 to give 2- or  
4-((9,10-dihydro-9,10-dioxoanthracen-2-yl)amino)-N-(4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) 
phenyl)sulfonyl) alkanamides 3a–c. Also, compound 4 was prepared by the same method on  
reaction of celecoxib 1 and 2-chloroethylisocyanate. The key intermediate 4 was then reacted with  
2-aminoanthraquinone 8 to give the desired product 5. Moreover the intermediate 6 was prepared by 
reaction of celecoxib 1 with 2,2'-dichlorodiethylamine hydrochloride in dry toluene. It was then reacted 
with 2-aminoanthraquinone 8 to produce 7 (Scheme 1). 
On the other hand 2-aminoanthraquinone 8 was reacted with the same series of chloroacyl chlorides 
or oxalyl dichloride to give the intermediates 2- or 4-chloro-N-(9,10-dihydro-9,10-dioxoanthracen-2-yl) 
alkanamides 9a–c, 9a was obtained according to a previously reported method [20] or 2-((9,10-dihydro-
9,10-dioxoanthracen-2-yl)amino)-2-oxoacetyl chloride 9d according to the reported method [21],  
which on reaction with celecoxib 1 gave the target compounds 10a–d. Compound 8 was also reacted 
with 2-chloroethylisocyanate to give the intermediate 11 according to the reported method [12]  
which was then reacted with celecoxib 1 to give the final compound 12 (Scheme 2). It is clear that 
compounds 3a–c are isomers for compounds 10a–c, while compound 10d can be obtained by applying 
the same method applied for preparation of compounds 3a–c. Again compound 5 is an isomer for 
compound 12. This may give an idea about the effect of isomerism on the activity of the final compounds. 
2.2. Pharmacological Screening 
It is well known that chemotherapy aims to destroy the cancer cells with various types of chemicals. 
The substances used are supposed to target mainly the cancer cells and doses are calculated to minimize 
the collateral damage to surrounding tissues, which nevertheless occurs [22]. This kind of treatment 
increases the entropy of the organism, suppresses the immune system, and forms a toxic cell environment 
which may destroy surrounding healthy cells [23], so it is important to minimize curing doses to the  
least amount possible to minimize the side effects of these drugs. The antitumor activities of the new 
compounds 3a–c, 7, 10a–d and 12 were assessed against the HEPG2 cancer cell line in comparison to 
the traditional anticancer drugs 5-flurouracil (5-FU) and doxorubicin (DOX). Regarding the antitumor 
activity results, all of the selected compounds showed reasonable antitumor activity in comparison to  
5-FU and DOX in concentration ranging from 3.92–9.38 µg/mL. Table 1 shows the cytotoxic activity  
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of the selected newly synthesized derivatives, where compounds 3c, 7 and 12 were the most active 
derivatives with IC50 equals 3.74, 4.31 and 3.92 respectively. 
Moreover, the biochemical effects of the selected derivatives on some enzymes such as alanine and 
aspartate aminotransferases (ALT and AST) and alkaline phosphatase (ALP), in addition to total lipids, 
cholesterol, triglycerides, bilirubin, albumin, globulin and creatinine in serum of mice were investigated. 
The study of the induced biochemical parameters of most of the tested compounds in mice showed 
insignificant differences relative to the control group which indicates a moderate safety margin for the 
selected compounds as shown in Tables 2–4. 
Scheme 1. General methods for the preparation of 2a–c, 3a–c, 4, 5, 6 and 7,  
Reagents and conditions: (a) Acid chloride, reflux, 1 h; (b) 2-Chloroethylisocyanate, 
reflux, 1 h; (c) 2,2'-Dichloroethylamine hydrochloride, dry toluene, reflux, 4 h; and  
(d) 2-Aminoanthraquinone, Dimethyl formamide (DMF), reflux, 4–8 h. 
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Scheme 2. General methods for the preparation of 9a–d, 10a–d, 11 and 12. Reagents  
and conditions: (a) Acid chloride, reflux, 1 h; (b) 2-Chloroethylisocyanate, reflux, 1 h;  
and (c) Celecoxib, ethanol, DMF, reflux, 4–5 h. 
 
Table 1. The antiproliferative effects of anthraquinone derivatives against hepatic carcinoma 
tumor cell line (HEPG2). 
Compound IC50 (μg·mL−1) 
3a 6.53 
3b 9.38 
3c 3.74 
7 4.31 
10a 8.48 
10b 7.43 
10c 8.54 
10d 6.59 
12 3.92 
5-Flurouracil 5.00 
Doxorubicin 3.56 
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Table 2. Biochemical effects (Mean ± SD (Standard Deviation) of treatment with  
5-flurouracil (5-FU), doxorubicin (DOX), and the anthraquinone derivatives on serum ALT, 
AST, and ALP in mice. 
Compounds ALT (IU/mL) AST (IU/mL) ALP (k.k./dL) 
3a 38.53 ± 6.50 *** 111.59 ± 12.80 ** 19.99 ± 4.39 *** 
3b 60.80 ± 9.20 * 157.28 ± 20.30 * 43.25 ± 7.08 * 
3c 67.39 ± 11.00 * 146.40 ± 28.10 * 36.90 ± 9.80 * 
7 39.10 ± 8.40 *** 126.20 ± 12.10 ** 18.76 ± 6.43 *** 
10a 45.51 ± 4.23 *** 108.66 ± 4.61 *** 21.77 ± 3.50 ** 
10b 54.2 ± 11.05 * 146.50 ± 28.90 * 46.47 ± 10.87 * 
10c 78.10 ± 13.30 * 141.20 ± 32.04 * 31.46 ± 9.45 * 
10d 48.07 ± 6.16 *** 112.09 ± 8.83 *** 17.79 ± 3.06 *** 
12 51.88 ± 11.50 ** 113.00 ± 9.52 ** 21.09 ± 3.48 ** 
Control 43.50 ± 2.03 108.32 ± 4.19 17.70 ± 1.10 
5-Flurouracil 51.47 ± 9.02 * 130.43 ± 8.92 * 25.49 ± 6.03 * 
Doxorubicin 59.26 ± 12.03 * 147.23 ± 16.34 * 30.32 ± 5.14 * 
* p < 0.001: Highly significant; ** p < 0.01: Significant; *** n.s.: Non significant; ALT: Alanine  
amino transferase; AST: Aspartate amino transferase; ALP: Alkaline phosphatase; and k.k./dL: Kind &  
King Unit/Dalton. 
Table 3. Biochemical effects (Mean ± SD) of treatment with 5-FU, DOX, and anthraquinone 
derivatives on total lipids, cholesterol, triglycerides, and bilirubin in mice. 
Compounds Total Lipids (mg/dL) Cholesterol (mg/dL) Triglycerides (mg/dL) Bilirubin (mg/dL) 
3a 336.40 ± 19.10 *** 97.20 ± 9.90 *** 117.90 ± 18.40 ** 0.67 ± 0.03 *** 
3b 379.20 ± 37.80 * 127.50 ± 25.10 * 136.10 ± 27.09 * 0.97 ± 0.05 * 
3c 321.70 ± 18.90 *** 92.80 ± 14.30 *** 115.40 ± 8.70 *** 0.63 ± 0.05 *** 
7 329.60 ± 14.40 *** 97.40 ± 18.60 *** 114.90 ± 10.70 *** 0.64 ± 0.02 *** 
10a 313.70 ± 31.20 *** 94.80 ± 18.60 *** 117.31 ± 21.60 *** 0.55 ± 0.06 ** 
10b 374.60 ± 36.80 * 111.40 ± 16.50 ** 97.40 ± 9.60 *** 1.09 ± 0.60 * 
10c 375.26 ± 27.80 * 111.80 ± 31.40 ** 157.90 ± 35.70 * 0.74 ± 0.03 ** 
10d 328.50 ± 22.70 *** 96.39 ± 17.10 *** 115.51 ± 18.10 *** 0.54 ± 0.05 ** 
12 369.30 ± 26.30 * 109.90 ± 18.60 ** 114.20 ± 18.40 ** 0.73 ± 0.16 ** 
Control 323.41 ± 27.10 94.32 ± 13.50 108.70 ± 16.80 0.63 ± 0.04 
5-Flurouracil 378.20 ± 31.40 * 105.90 ± 11.70 * 126.50 ± 19.40 * 0.75 ± 0.10 * 
Doxorubicin 366.70 ± 6.10 * 109.30 ± 14.20 * 137.80 ± 17.10 * 0.81 ± 0.19 * 
* p < 0.001: Highly significant; ** p < 0.01: Significant; and *** n.s.: Non significant. 
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Table 4. Biochemical effects of treatment with 5-FU, DOX, and anthraquinone derivatives 
on serum albumin, globulin and creatinine in mice. 
Biochemical Parameters Albumin (mg/dL) Globulin (mg/dL) A/G Ratio Creatinine (mg/dL) 
3a 5.96 ± 0.4 *** 4.3 ± 0.69 *** 1.46 *** 0.62 ± 0.08 *** 
3b 6.43 ± 0.44 ** 6.46 ± 0.8 ** 1.001 * 0.73 ± 0.06 ** 
3c 5.65 ± 0.69 *** 4.67 ± 1.09 *** 1.13 *** 0.66 ± 0.07 *** 
7 5.92 ± 0.86 *** 4.73 ± 0.87 *** 1.15 *** 0.85 ± 0.08 ** 
10a 5.95 ± 0.78 *** 5.16 ± 0.7 *** 1.15 *** 0.72 ± 0.08 *** 
10b 6.81 ± 0.47 ** 6.79 ± 0.7 ** 1.02 * 1.62 ± 0.07 * 
10c 10.26 ± 1.31 * 8.97 ± 0.9 * 1.14 ** 0.73 ± 0.03 *** 
10d 5.53 ± 0.71 *** 4.88 ± 1.01 *** 1.13 *** 0.68 ± 0.04 *** 
12 7.4 ± 0.59 ** 6.65 ± 0.81 ** 1.006 * 0.8 ± 0.09 ** 
Control 5.63 ± 0.51 4.32 ± 0.9 1.3 0.69 ± 0.03 
5-FU 6.49 ± 0.92 ** 5.75 ± 0.8 ** 1.13 ** 0.81 ± 0.06 ** 
DOX 6.37 ± 0.85 ** 5.91 ± 0.63 ** 1.078 ** 0.78 ± 0.04 ** 
* p < 0.001: Highly significant; ** p < 0.01: Significant; and *** n.s.: Non significant. 
Data in Table 2 present the liver enzymatic activities (ALT, AST and ALP) in serum of control and 
treated groups of mice. The results showed that the values recorded for AST and ALT were significantly 
higher (p < 0.001) with 5-FU and DOX treated groups of mice than the control. On the other hand, 
treatment with the new compounds tested, caused inverse effects, where some values recorded for AST 
and ALT were non significant (n.s.) or slightly higher (p < 0.01) in comparison to control. Moreover, 
the recorded data showed that ALP activities were significantly increased (p < 0.001) with the treatment 
with 5-FU and DOX, while there were no significant changes in ALP activities upon treatment with 
some of the compounds. 
Data listed in Table 3 demonstrate the comparison between the levels of total lipids, cholesterol, 
triglycerides and bilirubin in serum of treated mice and the control group. It can be deduced from the 
present data that 5-FU and DOX caused a significant increase in the level of these parameters while 
treatment with the new derivatives tested showed moderate or no significant changes. 
Table 4 represents a comparison between the levels of albumin, globulins and creatinine in serum of 
control and treated groups of mice. It is clear from these results that there was a slight increase in the 
level of albumin and creatinine and globulins in the 5-FU and DOX treated groups of mice while there 
were moderate or non significant changes in the other treated groups. 
Based on these findings in the present work, the compounds in this study would have better biological 
activity as anti-proliferative agents with less toxic side effects. 
2.3. Molecular Docking Study 
Molecular docking is a frequently used tool in computer-aided structure-based rational drug design. 
It evaluates how small molecules called (e.g., drug candidates) and the target macromolecule (receptor 
or enzyme) fit together. AutoDock Tools (ADT) is a program package of automated docking tools that 
is available from http://autodock.scripps.edu/. It is designed to predict how small molecules bind to  
a target protein of known 3D-structure. Besides generating binding energies in these docking studies, 
the position of the ligand in the host’s binding site can be visualized. It can be useful for developing 
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better drug candidates and also for understanding the nature of the binding. In this study, two classes of 
compounds were involved, including: first, the non-receptor tyrosine kinase SRC (Pp60v-src; pdb code: 
1skj). Second, the c-Kit receptor PTK: Platelet-derived growth factor receptor (PDGFR, c-Kit; pdb code: 
1t46). The deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The 
activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells [24]. 
2.3.1. Evaluation of Docking Performance and Accuracy into Different PTKs 
As cited in (Tables 5 and 6), the Root Mean Square Deviation (RMSD) values of the co-crystallized 
ligands UR2 and 1skj in the two PTKs involved, are 1.84 and 0.39 Å, respectively. It was found that the 
docked ligands are exactly superimposed with the originally embedded native ligands especially into  
c-Kit PTK, not only for the best-scored conformations, but also for all the docked conformations  
(Figure 1A,B). The docked STI-571 ligand (Imatinib or Gleevec), 4-(4-methylpiperazin-1-yl-methyl)-N-[4-
methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]benzamide, into its c-Kit receptor PTK (pdb code: 
1t46), exhibited the best RMSD of 0.39 Å, and a low binding free energy (∆Gb) of −15.85 kcal/mol. The 
docking results of the natively embedded ligands of PTKs were reasonably well comparable and well 
correlated to their biological methods [25,26]; Hence these results indicated that flexible docking 
involving AutoDock 4.2 under our experimental parameters seems to be accurate, with small RMSD 
values highly resembling the biological co-crystallization. 
Figure 1. Validation of AutoDock 4.2 programs by docking of the native co-crystallized ligands 
UR2 and STI of 1skj and 1t46 into their binding sites, in (A) and (B), respectively. The native 
ligands are shown in yellow sticks, while the docked ones are shown in balls and sticks, colored 
by element. Their hydrogen bonds are shown as blue and green dotted lines, respectively. The 
docked STI ligand seems exactly superimposed on the native one within 0.39 Å RMSD, whereas 
UR2 ligand seems partially overlapped on the native one within 1.84 Å RMSD. 
(A) 
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Figure 1. Cont. 
 
(B) 
2.3.2. Docking Study of the Synthesized Compounds 
Docking of our novel compounds into the nonreceptor tyrosine kinase SRC (Pp60v-src; pdb code: 
1skj), indicated that compounds revealing the best results include compounds: 3a, 10a, 10b, and 10d. 
They exhibited the lowest binding free energies (∆Gb) being: −11.57, −10.89, −11.17 and −11.73 kcal/mol, 
respectively with RMSD range of 1.43–4.20 Å. Moreover, they bind into PTK through up to five 
hydrogen bonds, involving their common moieties being: Anthraquinone C=O, SO2NH, and O=CNH 
which were bound to the commonly involved amino acids being: Arg12 (NH), His58 (C=O), Lys60 
(NH), Thr72 (OH), and Arg62 (NH), as cited in Table 5. 
Table 5. The flexible docking results (AutoDock 4.2), regarding the binding free energies 
(ΔGb) and inhibition constants (Ki) of compounds docked into PTK (1skj). 
Comp. 
∆Gb a  
(kcal/mol) 
Ki b  
(nM) 
Hydrogen Bonds between Atoms of Compounds and 
Amino Acids of PTK (1skj) RMSD c 
(Å) Atoms of 
Compounds 
Amino Acids 
Distance 
(Å) 
Angle 
(°) 
3a −11.57 3.31 Ph–N HN of Lys60 2.48 154.9 1.43 
3b −10.86 10.94 Anthraquinone C=O HN of His58 2.27 140.6 4.19 
Terminal C–F HN of Arg12 2.29 168.3 
3c −10.56 18.04 –SO2NHC=O HN of Lys60 1.90 172.1 5.60 
7 −9.86 59.49 
S=O 1 1HN of Arg12 2.39 134.4 
5.72 S=O 2 1HN of Arg12 2.24 134.9 
S=O 2 2HN of Arg12 2.07 140.1 
10a −10.89 10.40 Anthraquinone C=O HN of His58 2.31 123.8 4.20 
10b −11.17 6.45 
Anthraquinone C=O HN of Arg12 1.91 135.8 
2.01 
CONH O=C of His58 1.91 142.0 
SO2NH O=C of His58 2.22 150.1 
SO2HN HN of Lys60 2.47 164.0 
Pyrazole=N HN of Arg62 2.47 100.8 
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Table 5. Cont. 
Comp. 
∆Gb a  
(kcal/mol) 
Ki b  
(nM) 
Hydrogen Bonds between Atoms of Compounds and 
Amino Acids of PTK (1skj) RMSD c 
(Å) 
Atoms of Compound. Amino Acids 
Distance 
(Å) 
Angle 
(°) 
10c −9.69 78.94 
Anthraquinone C=O HN of Arg62 2.07 159.3 
5.80 
–S=O 1 HN of Lys60 1.92 144.1 
–S=O 2 HN of Lys60 1.91 126.4 
SO2NH O=C of His58 2.24 150.2 
10d −11.73 2.53 Pyrazole=N HN of Lys60 1.97 155.1 1.67 
12 −9.85 59.82 CONH O=C of His58 1.74 142.4 3.87 
HNS=O HN of Lys60 1.97 162.5 
UR2 d −11.61 3.11 
Terminal COO HN of His58 2.27 146.4 
1.84 
HNC=O HN of Lys60 2.32 124.5 
Terminal P=O 1 HN of Arg62 2.44 122.4 
Terminal P=O 2 HN of Arg62 2.35 140.5 
a Binding free energy; b Inhibition constant; c Root mean square deviation; d 4-[3-Carboxymethyl-3-(4-
phosphonooxybenzyl)ureido]-4-[(3-cyclohexylpropyl)methylcarbamoyl]butyric acid; 1 and 2 indicate the 
specific atom involved in the hydrogen binding when there is two or more similar groups. 
As illustrated in Figure 2, compound 3c possess high potential binding affinity (∆Gb: −10.56 kcal/mol) 
into the binding site of the 3D macromolecule (PTK, 1skj). Its high affinity is presumably attributed to 
formation of one hydrogen bonds between its sulfone S=O and HN of Lys60 amino acid of the binding 
site. Compound 3c was docked partially superimposed onto the native ligand (UR2) into the binding 
pocket of PTK within RMSD being 5.60 Å. 
Figure 2. The binding affinities of compounds 3c; Ball and stick, colored by elements,  
(grey = carbon, red = oxygen, blue = nitrogen, and yellow = sulfur) involving flexible 
docking into 1skj PTk. Compound 3c (ΔGb: −10.56 kcal/mol; RMSD: 5.60 Å) is partially 
superimposed onto the Ur2 native ligand; Yellow sticks, and it exhibited one hydrogen bonds 
(green dashed lines) with Lys60. PTK binding site is shown with solid surface. 
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The docking of our compounds into c-Kit receptor PTK: Platelet-derived growth factor receptor 
(PDGFR, c-Kit, pdb code: 1t46), indicated that compounds revealing the best results include compounds: 
3a, 10a, 10b, and 10d. They exhibited the lowest binding free energies (∆Gb) of −13.20, −13.37, −12.63, 
and −14.22 kcal/mol, respectively with RMSD range of 4.29–5.98 Å. They bind into PTK through up to 
three hydrogen bonds, involving their common moieties being: Ph–NH, Ph–NH–C=O, anthraquinone 
C=O, and SO2NH which bound to the commonly involved amino acids being: Glu640 (C=O), Thr670 
(OH), Asp810 (C=O, NH), and Lys623 (NH) as cited in Table 6. 
Table 6. The flexible docking results (AutoDock 4.2), regarding the binding free energies 
(ΔGb) and inhibition constants (Ki) of compounds docked into c-Kit PTK (1t46). 
Comp. 
∆Gb a  
(kcal/mol) 
Ki b 
Hydrogen Bonds between Atoms of Compounds and Amino 
Acids of PTK (1t46) RMSD c 
(Å) 
Atoms of Comp. Amino Acids 
Distance
(Å) 
Angle 
(°) 
3a −13.20 212.15 pM –SO2NH O=C of Glu640 2.46 175.8 5.98 
3b −9.91 54.76 nM Ph–NH O=C of Asp810 1.92 153.6 10.0 
3c −10.56 18.09 nM d 10.05 
7 −9.83 62.78 nM 
Ph–NH O=C of Asp810 2.34 114.2 
9.46 
Ph–NHCH2NH O=C of Asp81 2.26 112.1 
Ph–NHCH2NH O–C of Asp810 1.96 145.7 
Terminal C–F HN of Arg791 2.12 122.6 
10a −13.37 157.86 pM Ph–NH O=C of Asp810 2.19 122.4 4.36 
Ph–NH O=C of Glu640 1.75 105.4 
10b −12.63 555.42 pM Anthraquinone C=O HN of Asp810 2.35 129.6 5.66 
Ph–NHC=O HN of Lys623 2.41 103.0 
10c −12.01 1.57 nM 
Anthraquinone C=O a HO of Thr670 2.39 100.6 
5.31 Anthraquinone C=O b O=C of Glu640 2.02 144.5 
Ph–NH HN of Lys623 2.38 124.9 
10d −14.22 37.78 pM 
Anthraquinone C=O HO of Thr670 2.22 110.1 
4.29 Ph–NH O=C of Glu640 1.91 162.8 
Ph–NHC=O HN of Asp810 2.33 104.5 
12 −11.86 2.02 nM Ph–NH CO of Asp792 2.05 130.2 10.84 
Terminal C–F NH of Ile789 2.29 
STI e −15.85 2.41 pM Ph–C=O HN of Asp810 2.25 146.3 0.39 
Ph–NH OH of Thr670 2.13 130.9 
a Binding free energy; b Inhibition constant; c Root mean square deviation; d No hydrogen bond detected;  
e 4-(4-Methylpiperazin-1-yl methyl)-n-[4-methyl-3-(4-pyridin-3-yl pyrimidin-2-yl amino)phenyl]benzamide. 
To investigate the potential PTK inhibition, the comparatively effective antiproliferative derivatives 
against HEPG2, namely 10d and 12 were docked into PTK (1t46) as shown in detail in (Figure 4). 
Compound 10d revealed the highest binding affinities into the binding sites of PTK (∆Gb:  
−14.22 kcal/mol) with three hydrogen bonds between its anthraquinone C=O, Ph–NH, and Ph–NHC=O 
moieties and Glu640 (C=O), Thr670 (OH), and Asp810 (NH) amino acids. Additionally, the RMSD is 
of 4.29 Å and it is seen docked deeply into the binding pocket. Also, compound 12 was tightly bound 
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into PTK through two hydrogen bonds via its Ph-NH and terminal C–F groups and Asp792 (C=O) and 
Ile789 (NH) with (∆Gb: −11.86 kcal/mol) and RMSD of 10.84 Å. 
Figure 3. Comparative docking modes of compounds 10d (blue sticks) and 12 (ball and 
stick, colored by elements; grey = carbon, red = oxygen, blue = nitrogen, and yellow = 
sulfur), involving flexible docking into 1t46, c-Kit-PTK. Compounds 10d and 12 exhibited 
three and two hydrogen bonds, respectively. Compound 10d is shown superimposed 
(RMSD: 4.29 Å) onto the STI ligand (red lines). Compound 12 was partially shifted from 
the STI ligand (RMSD: 10.84 Å). PTK is shown as a solid backbone ribbon for protein and 
its binding site is shown in a yellow solid surface view with labeled amino acids. 
 
In the analysis of docking results, a good overall correlation exists between the biological results  
(IC50 (μg·mL−1) against HEPG2 tumor cells) and their corresponding binding affinities predicted by 
AutoDock into the corresponding 1skj (Pp60v-src) tyrosine kinase. Many compounds, namely 3a, 3b, 
and 10a–10d, again revealed a reasonable correlation coefficient (R2) of 0.487 as represented in  
Figure 4A. These compounds revealed better correlation coefficient (R2) between their biological results 
(IC50 (μg·mL−1) against HEPG2 tumor cells and binding free energies (∆Gb) into 1t46 (PDGFR, c-Kit) 
tyrosine kinase, being of 0.656 as represented in Figure 4B. 
Figure 4. The overall correlation between IC50 against HEPG2 tumor cell line and the 
binding free energies (ΔGb) for compounds 3a, 3b, and 10a–10d against 1skj PTK (plot A), 
and against 1t46 PTK (plot B). 
 
(A) 
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Figure 4. Cont. 
 
(B) 
Accordingly, from the aforementioned correlations between the biological activity and molecular 
docking results, we can conclude that our compounds in this study are proposed to act via inhibition of 
the c-Kit receptor PTK: Platelet-derived growth factor receptor (PDGFR, c-Kit; pdb code: 1t46) more 
than through the non-receptor tyrosine kinase SRC (Pp60v-src; pdb code: 1skj). 
3. Experimental Section 
3.1. Chemistry 
Melting points were obtained on a Barnstead 9001 Electrothermal melting point apparatus  
(Chula Vista, CA, USA) and are uncorrected. IR spectra were recorded on a Perkin Elmer FT-IR 
Spectrum BX Spectrometer (Waltham, MA, USA) at cm−1 scale using KBr discs. 1H NMR and 13C NMR 
were recorded on a JEOL 300 MHz Spectrometer (Tokyo, Japan), Japan and chemical shift values  
were expressed in δ values (ppm) relative to tetramethylsilane (TMS) as internal standard. Coupling 
constants are given in Hz. The mass spectra were recorded on GCMC-QP 1000 EX Shimadzu Gas 
Chromatography MS spectrometer (Kyoto, Japan), Japan E.I.70 ev. Elemental analysis (C, H, N) were 
carried out at the Micro analytical Center, Faculty of Science, Cairo University, Cairo, Egypt, and were 
in full agreement with the proposed molecular weights within ± (0.2%–0.3%) of the theoretical values. 
All reagents were of commercial quality and were used without further purification. Organic solvents 
were dried in the presence of an appropriate drying agent and were stored over suitable molecular sieves. 
Reaction progress was monitored by analytical thin layer chromatography (TLC) on precoated  
(0.75 mm) silica gel GF254 plates and the products were visualized by UV light. 
3.1.1. N-2-Chloroacyl-4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (2a) 
According to Reported Method [19]. N-(2- or 4-Chloroalkyl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-
pyrazol-1-yl] Benzene Sulfonamide (2b,c). A mixture of celecoxib 1 (0.01 mol) and 1,2-chloropropionyl 
chloride, or chlorobutyryl chloride (0.04 mol) was heated under reflux for 1 h, the mixture  
was concentrated by evaporation under vacuum, after cooling the reaction mixture was poured onto ice  
cold water and the solid formed was filtered off, dried and recrystallized from ethanol to give the 
compounds 2b,c respectively. 
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3.1.2. N-(2-Chloropropionyl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (2b) 
Yield 82%; m.p.: 144–146 °C; IR (νmax/cm−1): 3232 (NH), 1732 (C=O); 1H NMR (DMSO-d6) δ: 1.40 
(d, J = 6.5 Hz, 3H, CH3), 2.20 (s, 3H, Ar–CH3), 4.40 (q, 1H, CH–Cl), 6.67 (s, 1H, pyrazole-H),  
7.19–7.95 (m, 9H, Ar–H + NH); 13C NMR (DMSO-d6) δ: 20.6 (CH3), 21.3 (Ar–CH3), 56.5 (Cl–CH), 
106.1, 125.3, 125.9, 126.7, 128.7, 129.3, 139.0, 141.0, 142.6, 143.9, 145.2, 154.5 (CF3, Ar–C and C=N), 
175.2 (C=O); MS: m/z (%): 471, 473 (M+, M+2, 28.8, 11.2) 
3.1.3. N-(4-Chlorobutyryl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (2c) 
Yield 75%; m.p.: 135 °C; IR (νmax/cm−1): 3244 (NH), 1735 (C=O); 1H NMR (DMSO-d6) δ: 2.0  
(m, 2H, CH2–CH2–CH2), 2.3 (s, 3H, Ar–CH3), 2.39 (t, J = 7.5 Hz, 2H, COCH2), 3.8 (t, J = 7.5 Hz, 2H, 
CH2Cl), 6.67 (s, 1H, pyrazole–H), 7.0 (d, J = 8 Hz, 2H, H-3, 5 p-tolyl), 7.1 (d, J = 8 Hz, 2H, H-2,  
6 p-tolyl), 7.4 (d, J = 9 Hz, 2H, H-2, 6 benzene sulfonamide), 7.9 (d, J = 9 Hz, 2H, H-3, 5 benzene 
sulfonamide); 13C NMR (DMSO-d6) δ: 18.2 (CH2–CH2–CH2), 22.9 (CH3), 30.3 (CH2CO), 47.3 (CH2Cl), 
106.4, 125.3, 125.6, 128.7, 129.1, 129.8, 130.8, 137.2, 139.9, 143.6, 145.3, 154.5 (CF3, Ar–C and C=N), 
173.2 (C=O); MS: m/z (%): 485, 487 (M+, M+2, 37.8, 13.2). 
3.1.4. General Method for Preparation of N-(2- or 4-(9,10-Dihydro-9,10-dioxoanthracen-2-yl) 
aminoacyl) 4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (3a–c) 
To a solution of 2a–c (0.01 mol) in ethanol (15 mL), 2-aminoanthraquinone 8 (0.01 mol) in DMF  
(3 mL) was added. The mixture was then heated to reflux for 4–5 h, the excess solvent was removed 
under vacuum and after cooling the precipitate formed was collected by filtration, washed with water 
and recrystallized from the proper solvent to obtain 3a–c, respectively. 
3.1.5. N-(2-(9,10-Dihydro-9,10-dioxoanthracen-2-yl) aminoacetyl)-4-[5-(p-tolyl)-3-trifluoromethyl-
1H-pyrazol-1-yl] benzene sulfonamide (3a) 
Yield 70%; Crystallized from ethanol; m.p.: 156–158 °C; IR (νmax/cm−1): 3345, 3234 (2NH),  
1673 (br., 3C=O); 1H NMR (DMSO-d6) δ: 2.30 (s, 3H, Ar–CH3), 4.30 (s, 2H, N–CH2), 6.67 (s, 1H, 
pyrazole–H), 7.0–7.1 (d, d, J = 8 Hz, 2H, H-3, 4 anthraquione), 7.36 (s, 1H, H-1, anthra quinone),  
7.4 (d, J = 8.5 Hz, 2H, H-3, 5 p-tolyl), 7.6–8.1 (m, 10 H, Ar–H), 8.9 (br. s, 2H, 2NH); 13C NMR  
(DMSO-d6) δ: 21.3 (Ar–CH3), 29.7 (CH2), 106.3, 109.6, 118.0, 121.0, 126.1, 126.3, 126.4, 126.7, 128.7, 
128.9, 129.60, 133.0, 133.3, 133.7, 134.3, 134.9, 137.6, 139.2, 142.3, 154.7 (CF3, Ar–C and C=N), 
173.9, 180.1, 183.3 (3C=O); MS: m/z (%): 644 (M+, 14.7). 
3.1.6. N-(2-(9,10-Dihydro-9,10-dioxoanthracen-2-yl)-aminopropionyl)-4-[5-(p-tolyl)-3-
trifluoromethyl-1H pyrazol-1-yl] benzene sulfonamide (3b) 
Yield 75%; Recrystallized from dil. ethanol; m.p.: 261–263 °C; IR (νmax/cm−1): 3361, 3228 (2NH), 
1672, 1628 (3C=O); 1H NMR (DMSO-d6) δ: 1.4 (d, J = 6.5 Hz, 3H, CH–CH3), 2.2 (s, 3H, Ar–CH3),  
3.9 (q, 1H, CH–CH3), 6.67 (s, 1H, pyrazole-H), 7.0–7.1 (d, d, J = 8 Hz, 2H, H-3, 4 anthraquinone),  
7.3 (d, J = 8 Hz, 5, 2H, H-3, 5 p-tolyl), 7.4–8.1 (m, 11 H, Ar–H), 10.9 (br. s, 2H, 2-NH); 13C NMR  
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(DMSO-d6) δ: 17.6 (CH3), 21.3 (Ar–CH3), 59.5 (NH–CH), 109.2, 109.6, 110.2, 116.5, 118.0, 121.1, 
126.3, 126.9, 129.5, 133.0, 133.3, 133.7, 134.3, 134.9, 139.8, 141.3, 142.5, 144.6, 145.2, 154.7  
(CF3, Ar–C and C=N), 175.2, 180.0, 183.3 (3C=O); MS: m/z (%): 658 (M+, 12.9). 
3.1.7. N-(4-(9,10-Dihydro-9,10-dioxoanthracen-2-yl-aminobutanoyl)-4-[5-(p-tolyl)-3-trifluoromethyl-
1H-pyrazol-1-yl] benzene sulfonamide (3c) 
Yield: 82%, Recrystallized from CHCl3; m.p.: 214–216 °C, IR (νmax/cm−1): 3359, 3227 (2NH), 
1672 (br, 3C=O), 1H NMR (DMSO-d6) δ: 1.20 (m, 2H, –CH2–CH2–CH2), 2.02 (t, 2H, CH2–CO),  
2.30 (s, 3H, Ar–CH3), 3.80 (t, 2H, N–CH2), 6.67 (s, 1H, pyrazole–H), 7.02–7.1 (d, d, J = 8 Hz, 2H, H-3,  
4 anthra quione), 7.2 (s, 1H, H-1 anthraquinone), 7.3 (d, J = 8.5 Hz, 2H, H-3, 5 p-tolyl), 7.5 (d, J = 9 Hz,  
2H, H-2, 6 p-tolyl), 7.8–8.1 (m, 8H, Ar–H), 10.1, (br. s, 2H, 2-NH); 13C-NMR (DMSO-d6) δ: 17.8  
(CH2–CH2–CH2), 20.7 (Ar–CH3), 31.6 (–CH2CO), 47.3 (N–CH2), 106.3, 109.6, 118.0, 121.0, 126.1, 
126.3, 126.4, 126.7, 128.7, 128.9, 129.4, 129.6, 133.0, 133.3, 133.7, 134.3, 134.9, 137.6, 139.2, 142.3, 
154.7 (CF3, Ar–C and C=N), 173.9, 180.1, 183.3 (3C=O); MS: m/z (%): 672 (M+, 48.1). 
3.1.8. N-(2-Isocyanatoethyl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (4) 
A mixture of 1 (0.01 mol) and 2-chloroethyl isocyanate (0.04 mol) was heated under reflux for 1 h. 
The excess 2-chloroethylisocyanate was removed under vacuum, after cooling, the reaction mixture was 
poured into ice cold water the solid formed was filtered off, washed with water and recrystallized from 
ethanol to give compound 4 in 85% yield; m.p.: 115–117 °C; IR (νmax/cm−1), 3321 (NH), 1740 (C=O); 
1H NMR (CDCl3) δ: 2.30 (s, 3H, CH3–Ar), 3.60 (t, J = 6.5 Hz, 2H, CH2), 4.2 (t, J = 6.5 Hz, 2H, CH2), 
6.67 (s, 1H, pyrazole-H), 7.09 (d, J = 10 Hz, 2H, H-3, 5 p-tolyl), 7.18 (d, J = 11 Hz, 2H, H-2, 6 p-tolyl), 
7.4–8.03 (m, 5H, Ar–H and NH); 13C NMR (CDCl3) δ: 20.2 (CH3), 39.9, 41.8, (2CH2), 105.5, 124.1, 
124.2, 127.4, 128.0, 128.5, 134.9, 138.7, 142.7, 144.1, 147.3, 150.5, 150.9 (CF3, Ar–C, C=N and 
N=C=O); MS: m/z (%): 450 (M+, 10.5). 
3.1.9. N-(2-(3-(9,10-Dihydro-9,10-dioxoanthracen-2-yl) ureido) ethyl)-4-(5-(p-tolyl)-3-(trifluoro 
methyl)-1H-pyrazol-1-yl) benzene sulfonamide (5) 
To a solution of compound 4 (0.01 mol) in ethanol (15 mL), 2-aminoanthraquinone 8 (0.01 mol) in 
DMF (3 mL) was added. The mixture was then heated to reflux for 5 h. the excess solvent was removed 
under vacuum and after cooling the precipitate formed was collected by filtration, washed with water 
and recrystallized from ethanol to give compound 5 in 68% yield; m.p.: 221–223 °C; IR (νmax/cm−1):  
3435, 3345, 3200 (3NH), br. 1673 (3C=O); 1H NMR (DMSO-d6) δ: 2.3 (s, 3H, Ar–CH3), 3.7(t, J = 6.5 Hz, 
2H, CH2–NHSO2–), 3.96 (t, J = 6.5 Hz, 2H, CH2–NH–C=O), 6.67 (s, 1H, pyrazole-H), 6.94–6.96 (d, d, 
J = 8.5 Hz, 2H, H-3, 4 anthraquinone), 7.3 (d, J = 8.8 Hz, 2H, H-3, 5 p-tolyl), 7.6 (d, J = 9 Hz, 2H, H-2, 
6 p-tolyl), 7.84–8.08 (m, 9H, Ar–H), 8.25 (br. s, 3H, 3NH); 13C NMR (DMSO-d6) δ: 20.7 (CH3), 41.3, 
43.2 (2C, 2CH2), 109.6, 118.0, 121.0, 125.1, 126.2, 126.3, 126.4, 128.7, 129.2, 129.4, 129.6, 133.0, 
133.3, 133.7, 134.3, 134.8, 136.8, 139.1, 143.1, 145.4, 151.4, 151.8 (CF3, Ar–C and C=N), 154.7, 180.0, 
183.3 (3C=O); MS: m/z (%): 673 (M+, 3.75). 
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3.1.10. N-[2-(2-Chloroethylamino) ethyl]-4-[5-(p-tolyl)-3-trifluoromethyl-1H-pyrazol-1-yl] benzene 
sulfonamide (6) 
Bis (2-chloroethyl) amine hydrochloride (0.04 mol) was added to a solution of celecoxib 1 (0.02 mol) 
in dry toluene (10 mL) within 5 min in an ice bath and triethylamine (5 drops) was added and the reaction 
mixture was refluxed for 4 h. After the reaction was completed the solvent was concentrated, the residue 
was cooled and poured onto ice-cold water. The reaction mixture was then left at 5 °C overnight. The 
solid formed was collected by filtration and recrystallized from ethanol to give compound 6 in 84% 
yield; m.p.: 156–158 °C; IR (νmax/cm−1): 3340, 3234 (2NH), 1H NMR (DMSO-d6) δ: 2.2 (s, 3H,  
Ar–CH3), 2.5–2.55 (m, 6H, 3CH2NH), 3.8 (t, J = 6.5 Hz, 2H, CH2Cl), 6.7 (s, 1H, pyrazole-H), 7.10 (d, 
J = 8 Hz, 2H, H-3, 5 p-tolyl), 7.19 (d, J = 8 Hz, 2H, H-2, 6 p-tolyl), 7.5 (d, J = 8.8 Hz, 2H, H2, 6 benzene 
sulfonamide), 8.1 (d, J = 8.7 Hz, 2H, H-3, 5 benzene sulfonamide), 8.7 (s, 1H, NH), 11.02 (s, 1H, NH); 
13C NMR (DMSO-d6) δ: 20.2 (Ar-CH3), 39.5, 40.0, 40.7, 42.0 (4 CH2), 105.5, 124.2, 124.4, 127.5, 128.2, 
128.7, 135.0, 138.8, 142.8, 144.2, 150.6, 151.1 (CF3, Ar–C and C=N); MS: m/z (%): 523, 525 (M+, M+2, 
75.6, 27). 
3.1.11. N-[2-(2-(9,10-Dihydro-9,10-dioxoanthracen-2-yl) aminoethyl) aminoethyl]-4-[5-(p-tolyl)-3-
trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (7) 
A mixture of 6 (0.01 mol) in ethanol (15 mL), and 2-aminoanthraquinone 8 (0.01 mol) in DMF  
(3 mL) was heated under reflux for 8 h. The excess solvent was evaporated under vacuum and after 
cooling the solid formed was filtered off, washed well with water and recrystallized from methanol to 
give compound 7 in 73% yield; m.p.: 157–159 °C; IR (νmax/cm−1): 3415, 3351, 3234 (3NH), 1672 
(2C=O), 1618 (C=C); 1H NMR (DMSO-d6) δ: 2.2 (s, 3H, Ar–CH3), 2.53–2.64 (m, 8H, 4CH2), 6.67  
(s, 1H, pyrazole-H), 6.94–6.96 (d, d, J = 8.5 Hz, 2H, H-3,4 anthraquinone), 7.0 (d, J = 8 Hz, 2H, H-3,  
5 p-tolyl), 7.1 (d, J = 8.8 Hz, 2H, H-2, 6 p-tolyl), 7.2–8.1 (m, 11H, Ar–H and 2NH); 8.3 (br. s, 1H, NH), 
13C NMR (DMSO-d6) δ: 20.3 (Ar–CH3), 39.6, 40.1, 40.9, 42.2 (4CH2), 105.5, 117.2, 124.2, 124.4,  
125.1, 126.6, 126.7, 127.5, 128.3, 128.9, 129.2, 129.6, 133.0, 134.0, 134.5, 135.0, 137.8, 138.6, 142.8, 
143.1, 144.2, 150.6 (CF3, Ar–C and C=N), 173.8, 180.1, 183.3 (3CO); MS: m/z (%): 709, 711 (M+, M+2, 
68.8, 27). 
3.1.12. General Method for Preparation of 2- or 4-Chloro-N-(9,10-dihydro-9,10-dioxoanthracen-6-yl) 
alkanamide (9b,c) 
A mixture of anthraquinone 8 (0.01 mol) and 1,2-chloropropionyl chloride, or chlorobutyryl chloride 
(0.04 mol) was heated under reflux for 1 h, the mixture was concentrated by evaporation under vacuum, 
after cooling the reaction mixture was poured onto ice cold water and the solid formed was filtered off, 
dried and recrystallized from ethanol to give the compounds 9b,c respectively. 
3.1.13. 2-Chloro-N-(9,10-dihydro-9,10-dioxoanthracen-6-yl) propanamide (9b) 
Yield 78%; Crystallized from ethanol; m.p.: 168 °C; IR (νmax/cm−1): 3348 (NH), 1716, 1671 (3C=O); 
1H NMR (DMSO-d6) δ: 2.9 (d, J = 7.5 Hz, 3H, CH3), 5.5 (q, 1H, CHCl), 8.3 (s, 1H, H-1 anthraquinone), 
9–9.7 (m, 6 H, Ar–H), 10.2 (s, 1H, NH); 13C NMR (DMSO-d6) δ: 17.2 (CH3), 50.7 (CH), 111.9, 119.2,  
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122.0, 124.0, 124.6, 128.2, 128.3, 128.7, 129.0, 129.4, 137.1, (Ar–C), 162.6 (CO), 176.7, 177.4 (2CO 
anthraquinone); MS: m/z (%): 313, 315 (M+, M+2, 34.4, 13.5). 
3.1.14. 4-Chloro-N-(9,10-dihydro-9,10-dioxoanthracen-6-yl) butanamide (9c) 
Yield 75 %; Crystallized from dilute ethanol; m.p.: 219 °C; IR (νmax/cm−1): 3340 (NH), 1698, 1667, 
1649 (3C=O); 1H NMR (DMSO-d6) δ: 2.0 (m, 2H, CH2–CH2–CH2), 2.5 (t, J = 6.5 Hz, 2H, COCH2), 3.7 
(t, J = 6.5 Hz, 2H, CH2Cl), 7.9–8.2 (m, 6 H, Ar–H), 8.4 (s, 1H, Ar, H-1), 10.6 (s, H, NH); 13C NMR 
(DMSO-d6) δ: 27.5 (CH2–CH2–CH2), 33.5 (COCH2), 62.9 (CH2Cl), 115.7, 123.6, 126.6, 126.7, 127.7, 
128.4, 133.0, 134.1, 134.19, 134.5, 144.6 (Ar–C), 171 (C=O), 181.3, 182.4 (2C=O anthraquinone); MS: 
m/z (%): 327, 329 (M+, M+2, 28.4, 12.5). 
3.1.15. N-(9,10-Dihydro-9,10-dioxoanthracen-2-yl-amino-carbonyl)-4-[5-(p-tolyl)-3-trifluoromethyl-
1H-pyrazol-1-yl] benzene sulfonamide derivatives (10a–d) 
General method: A mixture of 9a–d (0.01 mol) in ethanol (15 mL), and celecoxib 1 (0.01 mol) in 
DMF (3 mL) was heated under reflux for 4–5 h. The excess solvent was evaporated under vacuum and 
the solid formed was filtered off, washed with water and recrystallized from the proper solvent to give 
compounds 10a–d. 
3.1.16. N-(9,10-Dihydro-9,10-dioxoanthracene-2-yl) aminoacetyl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-
pyrazol-1-yl] benzene sulfonamide (10a) 
Yield 70%; Recrystallized from chloroform; m.p.: 245–247 °C; IR (νmax/cm−1): 3345, 3114, (2NH), 
br. 1697 (3C=O); 1H NMR (DMSO-d6) δ: 2.5 (s, 3H, Ar–CH3), 4.37 (s, 2H, CH2), 6.68 (s, 1H,  
pyrazole-H), 6.94–6.96 (d, d, J = 8.5 Hz, 2H, H-3, 4 anthraquinone), 7.3 (d, J = 8 Hz, 2H, H-3,  
5 p-tolyl), 7.6 (d, J = 8.5 Hz, 2H, H-2, 6 p-tolyl), 7.84–8.1 (m, 9H, Ar–H) 8.45 (s,1H, NH), 10.9 (s, 1H, 
NH); 13C NMR (DMSO-d6) δ: 21.3 (CH3), 43.0 (CH2), 106.3, 109.2, 109.6, 110.2, 116.5, 117.2, 118.0, 
121.9, 125.1, 126.6, 126.7, 128.2, 129.6, 134.0, 134.3, 134.5, 143.9, 144.6, 145.2, 157.5 (CF3, Ar–C 
and C=N), 167.5, 181.3, 182.3 (3CO); MS: m/z (%): 644 (M+, 61.7). 
3.1.17. N-[1-(9,10-Dihydro-9,10-dioxoanthracene-2-yl) aminocarbonyl) ethyl]-4-[5-(p-tolyl)-3-tri 
fluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (10b) 
Yield 80%; Recrystallized from dil. ethanol; m.p.:132–135 °C; IR(νmax/cm−1): 3346, 3200 (2NH), 1690, 
1673 (3C=O); 1H NMR (DMSO-d6) δ: 1.6 (d, J = 6.5 Hz, 3H, CH3), 2.28 (s, 3H, Ar–CH3), 4.7 (q, 1H,  
CH–CH3), 6.67 (s, 1H, pyrazol-H), 6.94–6.96 (d, d, J = 8.5 Hz, 2H, H-3, 4 anthraquinone), 7.3 (d,  
J = 8 Hz, 2H, H-3, 5 p-tolyl), 7.6 (d, J = 8.5 Hz, 2H, H-2, 6 p-tolyl), 7.84–8.1 (m, 9H, Ar–H)  
8.46 (s, 1H, NH), 10.99 (s, 1H, NH); 13C NMR (DMSO-d6) δ: 16.5 (CH3), 20.7 (CH3–Ar), 52.7 (CH), 
106.3, 109.6, 118.0, 121.9, 126.1, 126.3, 126.7, 128.7, 128.9, 129.6, 133.0, 133.3, 133.7, 134.3, 134.9, 
137.6, 139.2, 142.3, 154.7 (CF3, Ar–C and C=N), 173.9, 180.1, 183.3 (3C=O); MS: m/z (%): 658  
(M+, 30). 
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3.1.18. N-[3-(9,10-Dihydro-9,10-dioxoanthracene-2-yl) aminocarbonyl) propyl]-4-[5-(p-tolyl)-3-tri 
fluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (10c) 
Yield 78%; Recrystallized from ethanol; m.p.: 113–115 °C; IR (νmax/cm−1): 3343, 3200 (2NH), 1690, 
1673 (3C=O); 1H NMR (DMSO-d6) δ: 1.96 (m, 2H, CH2CH2CH2), 2.1 (t, J = 6.5 Hz, 2H, CH2CO) 2.2 
(s, 3H, CH3–Ar), 2.6 (t, J = 6.5 Hz, 2H, N–CH2), 6.6 (s, 1H, pyrazole-H), 6.94–6.96 (d, d, J = 8.5 Hz, 
2H, H-3, 4 anthraquinone), 7.3 (d, J = 2 Hz, 2H, H-3, 5 p-tolyl), 7.6 (d, J = 9 Hz, 2H, H-2, 6 p-tolyl), 
7.84–8.1 (m, 9H, Ar-H), 8.4 (s, 1H, NH), 8.46 (s, 1H, NH); 13C NMR (DMSO-d6) δ: 21.3 (CH3), 29.7 
(CH2–CH2–CH2), 32.8 (CH2CO), 48.5 (CH2-N), 106.3, 115.7, 124.7, 125.4, 125.7, 127.2, 127.5, 128.7, 
129.7, 133.5, 133.6, 133.9, 134.2, 139.8, 141.3, 142.5, 144.6, 145.2, (CF3, Ar–C and C=N), 175.0, 180.0, 
183.3 (3C=O); MS: m/z (%): 672 (M+, 46.6). 
3.1.19. N-(9,10-Dihydro-9,10-dioxoanthracene-2-yl)aminooxalyl)-4-[5-(p-tolyl)-3-trifluoromethyl-1H-
pyrazol-1-yl] benzene sulfonamide (10d) 
Yield 72%; Recrystallized from chloroform/pet. ether; m.p.: 132–135 °C; IR (νmax/cm−1): 3415, 3245 
(2NH), 1728, 1620 (4 C=O); 1H NMR (DMSO-d6) δ: 2.2 (s, 3H, Ar–CH3), 6.69 (s, 1H, pyrazole-H), 7.2 
(d, J = 8 Hz, 2H, H-3, 5 p-tolyl), 7.5–8.1 (m, 13H, Ar-H), 8.7 (s, 1H, NH), 11.02 (s, 1H, NH); 13C NMR 
(DMSO-d6) δ: 106.3, 109.60, 110.2, 116.5, 117.2, 118.0, 121.9, 125.1, 126.6, 126.7, 128.2, 129.6, 133.0, 
134.0, 134.3, 134.5, 143.9, 144.6, 145.2, 157.5 (CF3, Ar–C and C=N), 173.2, 180.1, 183.3 (4C=O); MS: 
m/z (%): 658 (M+, 44). 
3.1.20. 2-(2-Isocyanatoethylamino)anthracene-9,10-dione (11) 
A mixture of 8 (0.01 mol) and 2-chloroethyl isocyanate (0.04 mol) was heated under reflux for 1 h. 
The excess 2-chloroethylisocyanate was removed under vacuum, after cooling, the reaction mixture was 
poured onto ice cold water the solid formed was filtered off, washed with water and recrystallized from 
ethanol to give compound 11 in 75% yield; m.p.: 144 °C; IR (νmax/cm−1): 3343 (NH), 1735, 1708, 1668 
(3C=O); 1H NMR (DMSO-d6) δ: 4.1 (t, J = 7.5 Hz, 2H, CH2NCO), 3.9 (t, J = 7.5 Hz, 2H, HN–CH2), 
7.9–8.1 (m, 6H, Ar–H), 8.4 (s, 1H, Ar, H-1), 8.9 (s, 1H, NH); 13C NMR (DMSO-d6) δ: 49.9 (CH2), 58.7 
(CH2), 115.7, 123.6, 126.6, 126.7, 127.7, 128.4, 133.0, 134.1, 134.19, 134.5, 144.6 (Ar–C), 173.9 
(N=C=O), 181.3, 182.4 (2C=O anthraquinone); MS: m/z (%): 292 (M+, 14.5). 
3.1.21. N-[2-(9,10-Dihydro-9,10-dioxoanthracene-2-yl-amino) ethylcarbamoyl]-4-[5-(p-tolyl)-3- 
trifluoromethyl-1H-pyrazol-1-yl] benzene sulfonamide (12) 
A mixture of 11 (0.01 mol) in ethanol (15 mL), and celecoxib 1 (0.01 mol) in DMF (3 mL) was heated 
under reflux for 5 h. The excess solvent was evaporated under vacuum and after cooling the solid formed 
was filtered off, washed with water and recrystallized. Yield 75%; crystallized from dil. ethanol; m.p.: 
162–164 °C; IR (νmax/cm−1): 3306, 3220 (3NH), 1671 (br., 3C=O); 1H NMR (DMSO-d6) δ: 2.2 (s, 3H, 
Ar-CH3), 3.4 (m, 2H, CH2), 4.1 (m, 2H, CH2), 6.6 (s, 1H, pyrazole-H), 7.02–7.1 (d, d, J = 8 Hz, 2H,  
H-3, 4 anthraquione), 7.2 (s, 1H, H-1, anthra quinone), 7.3 (d, J = 8.5 Hz, 2H, H-3, 5 p-toplyl), 7.5 (d,  
J = 9 Hz, 2H, H-2, 6 p-tolyl), 7.8–8.1 (m, 8H, Ar-H), 9.48 (s, 1H, NH), 10.09 (s, 1H, NH), 10.4 (s, 1H, 
NH); 13C NMR (DMSO-d6) δ: 20.7 (Ar–CH3), 43.8, 50.5 (2CH2), 106.3, 115.7, 123.5, 124.7, 125.4, 
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125.9, 126.5, 126.7, 127.2, 127.5, 128.7, 129.3, 133.5, 134.0, 139.8, 141.3, 142.5, 144.6, 145.2 (CF3, 
Ar–C and C=N), 175.2, 181.2, 183.3 (3C=O); MS: m/z (%): 673 (M+, 42). 
3.2. Pharmacological Screening 
3.2.1. Measurement of Potential Cytotoxicity by Sulforhodamine B (SRB) Assay 
The selected derivatives (compounds 3a–c, 7, 10a–d and 12), were subjected to a screening system 
for evaluation of their antitumor activity against liver HEPG2 cancer cell lines in comparison to  
the known anticancer drugs: 5-FU and DOX. Potential cytotoxicity of the compounds in this study  
was investigated using the method of Skehan et al. [27]. Cells were plated in 96-multiwell plate  
(104 cells/well) for 24 h before treatment with the compounds to allow attachment of cells to the wall of 
the plate. Different concentrations of the compound under test (0, 1, 2.5, 5, 10 µg/mL) were added to the 
cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated 
with the compounds for 48 h at 37 °C and in an atmosphere of 5% CO2. Cultures were then fixed with 
trichloroacetic acid and stained for 30 min with 0.4% (w/v) sulforhodamine B (SRB) dissolved in 1% 
acetic acid. Unbound dye was removed by four washes with 1% acetic acid, and protein-bound dye  
was extracted with 10 mM unbuffered tris base (tris hydroxymethyl aminomethane, Meryer Chemical 
Technology Co., Shanghai, China) for determination of optical density in a computer-interfaced, 96-well 
micro titer plate reader. The relation between surviving fraction and drug concentration is plotted to get 
the survival curve of both cancer cell lines after the specified compound. 
3.2.2. Biochemical Analysis 
Male albino mice weighing 18–20 g were used in the present study. Mice were divided into  
three main groups as follows: Untreated or control group (5 mice each), the second group is, divided 
into two subgroups (5 mice for each subgroup) and treated with 5-FU or DOX as reference anticancer 
drugs and the third group is divided into nine subgroups (5 mice for each subgroup) which was treated 
with the selected derivatives. In the control group each mouse was given a single inter peritoneal i.p. 
injection of 0.1 mL DMSO while the second and the third groups were given a single i.p. injection of 
0.1 mL containing 12 mg/kg body weight of the standard or tested compounds. 5-FU or DOX was 
dissolved in sterile water and the synthesized compounds were dissolved in DMSO. Blood was collected 
after 7 days from all mice groups. The biochemical effects of the selected compounds, on some liver 
enzymes such as aspartate, alanine aminotransferases (AST and ALT) [28] and alkaline phosphatase 
(ALP) [29], were analyzed using a blood auto analyzer (Olympus AV 400, Tokyo, Japan). Moreover, 
albumin [30], globulins [31], creatinine [32], total lipids [33], cholesterol [34], triglycerides and 
bilirubin [35] in serum of mice were evaluated in comparison to 5-FU and DOX. Statistical analysis 
of the results was performed using Chi-square values (SPSS computer program, IBM Corporation,  
NY, USA). 
3.3. Molecular Docking 
This protocol presents a detailed outline and advice for use of AutoDock (Molecular Graphics Lab., 
The Scripps Research Institute, La Jolla, CA, USA) and its graphical interface, AutoDock Tools, to 
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analyze biomolecular complexes using computational docking. The first step is to prepare the coordinate 
files for the docking molecule and the target molecule. The second step is the calculation of the affinity 
grid for the target molecule. In the third step, the docking molecule is docked with the affinity grid, and, 
finally, the results are analyzed. 
3.3.1. Preparing the Target Macromolecules Investigated 
Two different target protein tyrosine kinases were investigated. These include sarcoma proto-oncogenic 
kinase SRC (Pp60v-src) and platelet-derived growth factor receptor (PDGFR, c-Kit. Those were retrieved 
from the Protein Data Bank, http://www.rcsb.org/pdb/home/home.do. For each docking target, crucial 
amino acids of the active site were identified using data in PDBsum, http://www.ebi.ac.uk/pdbsum/. 
3.3.2. Preparing a Ligand File for AutoDock 
The ligands are originally drawn with a widely used chemical structure drawing software. The  
three-dimensional structures of the aforementioned compounds were constructed using Chem3D Ultra 
8.0 software (Chemical Structure Drawing Standard; Cambridge Soft Corporation, Cambridge, MA, 
USA, 2003) to obtain standard 3D structures (pdb format), then they were energetically minimized by 
using MOPAC with 100 iterations and minimum Root Mean Square (RMS) gradient of 0.10. It is 
recommended to confirm whether all hydrogen atoms are in the file before working with ADT. After 
opening the ligand, it can be visualized and ADT now automatically computes Gasteiger charges 
(empirical atomic partial charges) and distinguishes between hybridization state and type of each atom. 
As a part of preparation, the program determines rotatable bonds of the ligand to be able to generate 
different conformers for the docking. 
3.3.3. Setting the GRID Box, Preparing the GRID Parameter File, Running AutoGrid4, and 
Preparation of the Flexible Residue File 
The grid parameter file tells AutoGrid4 which receptor to compute the potentials around, the types of 
maps to compute and the location and extent of those maps. In general, one map is calculated for each 
atom type in the ligand plus an electrostatics map and a separate desolvation map. The types of maps 
depend on the types of atoms in the ligand. Thus one way to specify the types of maps is by choosing  
a ligand. The grid maps of 60 × 60 × 60 grid points, centered on the ligands of the complex structures, 
were used to cover the binding pockets. A spacing of 0.375 Å was set centered at −6.963, 60.886,  
and −9.54 Å, respectively for 1skj that encompassed the active site where the co-crystallized ligand; 
UR2: (4-[3-Carboxymethyl-3-(4-phosphonooxybenzyl)ureido]-4-[(3-cyclohexylpropyl)methylcarbamoyl] 
butyric acid), was embedded, was used to guide the docked inhibitors within PTK receptor, and flexible 
residues: GLU35, THR36, and ARG32. Whereas, The STI-571 ligand (Imatinib or Gleevec),  
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]benzamide, 
was centered into its c-Kit receptor PTK (pdb code: 1t46) at 27.696, 26.657, and 39.342 Å, respectively, 
that encompassed the active site where the co-crystallized ligand; STI-571, was embedded, and flexible 
residues: GLU640, THR670, and ASP810 were selected as key amino acids. Once those parameters 
were set in one file, AutoGrid calculates grid parameter files for each type of atom within a given area. 
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3.3.4. Preparing the Docking Parameter File and Running AutoDock4 
The docking parameter file indicates AutoDock which map files to use, the ligand molecule to move, 
what its center and number of torsions are, where to start the ligand, the flexible residues to move where 
side chain motion in the receptor is to be modeled, which docking algorithm to use and how many runs 
to do. It usually has the file extension, “.dpf”. Four different docking algorithms are currently available 
in AutoDock: SA, the original Monte Carlo simulated annealing; GA, a traditional Darwinian genetic 
algorithm; LS, local search; and GALS (Larmarckian genetic algorithm), which is a hybrid genetic 
algorithm with local search. Each search method has its own set of parameters, and these must be set 
before running the docking experiment itself. These parameters include what kind of random number 
generator to use, step sizes, etc. The most important parameters affect how long each docking will run. 
In GALS, the number of energy evaluations and the number of generations affect how long a docking 
will run. ADT lets you change all of these parameters, and others not mentioned here. In our study, we 
used AutoDock 4.2 to check the binding conformations of the synthesized compounds into different 
PTKs more accurately. Lamarckian genetic algorithm was used for all molecular docking simulations. 
Population size of 300, mutation rate of 0.02, and crossover rate of 0.8 were set as the parameters. 
Simulations were performed using up to 2.5 million energy evaluations with a maximum of 27,000 
generations. Each simulation was performed 10 times, yielding 10 docked conformations. The lowest 
energy conformations were regarded as the binding conformations between the ligands and the proteins. 
3.4. Analyzing the Docking Results 
Reading a docking log or a set of docking logs is the first step in analyzing the results of docking 
experiments. During its automated docking procedure, AutoDock outputs a detailed record to the result 
file has the extension “.dlg”. The output includes many details about the docking which are output as 
AutoDock parses the input files and reports what it finds. After completing the runs, AutoDock begins 
an analysis phase and records details of that process. At the very end, it reports a summary of the amount 
of time taken and the words “Successful Completion”. The key results in a docking log are the docked 
structures found at the end of each run, the energies of these docked structures and their similarities to 
each other. The similarity of docked structures is measured by computing the root-mean-square-deviation, 
RMSD, between the coordinates of the atoms. The docking results consist of the Protein Data Bank with 
Change (Q) and Torsions (T) (PDBQT) of the Cartesian coordinates of the atoms in the docked molecule, 
along with the state variables that describe this docked conformation and position. As a result of 
AutoDock calculations we obtain the output file with, in our case, ten conformers of the protein-ligand 
complex with flexible residues and the ligand located within the binding pocket. Each structure is scored 
and ranked by the program using the calculated interaction energy. 
4. Conclusions 
In this study, we have identified anthraquinone derivatives linked to celecoxib as a novel class of 
compound with anti-proliferative activity. Some of the new compounds (3c, 7, and 12) were the most 
potent in the biological assay employed (e.g., produced growth inhibition potential as compared to the 
reference anticancer drugs with no significant difference in biochemical parameters). These experimental 
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findings may provide support for the use of these novel compounds as new weapons in the fight against 
different types of cancer. 
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